The ALS community faces disappointment as Amylyx Pharmaceuticals’ drug Relyvrio fails to outperform a placebo in a study, raising questions about its approval in 2022. ALS advocate Mary Catherine Collet emphasizes the importance of facing the scientific data despite the setback. The drug generated significant revenue for the company, prompting discussions about its removal from the market and the FDA’s regulatory decisions. The case of Relyvrio highlights the challenges of balancing regulatory leniency with the need for effective treatments for incurable diseases like ALS. The community must now grapple with the implications of this latest setback in ALS research.
Source link
Amylyx ALS drug failure raises questions and concerns
